Cytopia targeting protein kinases
Wednesday, 18 June, 2008
Melbourne biotech Cytopia (ASX: CYT) is to present data from its study on FMS inhibitors at the Protein Kinase Targets oncology conference in Boston next week.
This will be the first formal disclosure of data from the study, in which a series of compounds discovered by Cytopia were found to inhibit the function of microphages, key cells in the immune system which also mediate inflammatory reactions.
One of the potential applications of the compounds is as a treatment of rheumatoid arthritis. The compounds are also showing potential as an inhibitor of the cells that cause bone osteolysis in advanced cancer sufferers.
Babies of stressed mothers likely to get their teeth earlier
Maternal stress during pregnancy can speed up the timing of teeth eruption, which may be an early...
Customised immune cells used to fight brain cancer
Researchers have developed CAR-T cells — ie, genetically modified immune cells manufactured...
Elevated blood protein levels predict mortality
Proteins that play key roles in the development of diseases such as cancer and inflammation may...
